Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 4Kidney Neoplasms 2Colorectal Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Recurrence 1Rectal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma 1Colonic Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Oxaliplatin 16Irinotecan 12Fluorouracil 12Leucovorin 10Bevacizumab 8pembrolizumab 7Cetuximab 7Capecitabine 7Nivolumab 5Gemcitabine 5Cyclophosphamide 5fludarabine 4aldesleukin 4Panitumumab 4Folfox protocol 4oblimersen 3Interleukin-2 3selpercatinib 2poly ICLC 2labetuzumab 2dehydroftorafur 2conatumumab 2cemiplimab 2bintrafusp alfa protein, human 2Tomography, X-Ray Computed 2Specimen Handling 2Receptor Protein-Tyrosine Kinases 2Radiotherapy 2Levoleucovorin 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Colonic Neoplasms × Interferon-alpha × Clear all
NCT00030342 2013-06-26

Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
60 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Colonic Neoplasms, Kidney Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡